Thomas Bhatt

Thomas Bhatt has been a pioneer in stereotactic body radiation therapy for localized prostate cancer and has contributed seminal data on its safety and efficacy. His research demonstrated that prostate cancer's unique radiobiology, with a low alpha/beta ratio, favors hypofractionated delivery schemes. He conducted pivotal trials establishing 5-fraction SBRT as an effective and well-tolerated alternative to conventional 40-45 fraction radiation for localized prostate cancer. His work helped establish SBRT as a guideline-recommended treatment option.